Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer

Oncotarget

Volumn 6, Issue 13, 2015, Pages 11310-11326

  Khan, Anm Nazmul H ^a   Kolomeyevskaya, Nonna ^a   Singel, Kelly L ^a   Grimm, Melissa J ^a   Moysich, Kirsten B ^a   Daudi, Sayeema ^a   Grzankowski, Kassondra S ^a   Lele, Sashikant ^a   Ylagan, Lourdes ^a   Webster, Gill A ^b   Abrams, Scott I ^a   Odunsi, Kunle ^a   Segal, Brahm H ^a,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Innate Immunotherapeutics   (New Zealand)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Macrophages; Myeloid derived suppressor cells; Ovarian cancer; Vaccination

Indexed keywords

CANCER VACCINE; MIS 416; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD11B; UNCLASSIFIED DRUG; CARD15 PROTEIN, MOUSE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD11B ANTIGEN; LIGAND; MIS416 VACCINE; OVALBUMIN; TLR9 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 9;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BONE MARROW CELL; CANCER IMMUNIZATION; CANCER SURVIVAL; CELL EXPANSION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG TARGETING; FEMALE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PERITONEUM MACROPHAGE; SURVIVAL TIME; TUMOR MICROENVIRONMENT; ADOPTIVE TRANSFER; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; COCULTURE; DISEASE COURSE; GENETICS; HUMAN; IMMUNOLOGY; MACROPHAGE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; T LYMPHOCYTE; TIME FACTOR; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR ESCAPE; VACCINATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11B; ASCITES; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; DISEASE PROGRESSION; FEMALE; HUMANS; LIGANDS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NOD2 SIGNALING ADAPTOR PROTEIN; OVALBUMIN; OVARIAN NEOPLASMS; T-LYMPHOCYTES; TIME FACTORS; TOLL-LIKE RECEPTOR 9; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; VACCINATION;

EID: 84929630740     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3597     Document Type: Article

References (50)

1. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, duPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012;109(15):5797-5802.
2. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC and Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203-213.
3. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538-18543.
4. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942-949.
5. Sabbatini P and Odunsi K. Immunologic approaches to ovarian cancer treatment. J Clin Oncol. 2007;25(20):2884-2893.
6. Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, Sun J, Moon EK, Fridlender ZG, Albelda S and Singhal S. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A. 2013;110(5):E415-424.
7. Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R, Ra HJ, Danet-Desnoyers G, Powell DJ, Jr. and Scholler N. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res. 2013;73(15):4820-4829.
8. Dangaj D and Scholler N. Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cellmediated antitumor responses. Oncoimmunology. 2013;2(8):e25913.
9. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L and Zou W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006;203(4):871-881.
10. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G and Zou W. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007;67(18):8900-8905.
11. Godoy HE, Khan AN, Vethanayagam RR, Grimm MJ, Singel KL, Kolomeyevskaya N, Sexton KJ, Parameswaran A, Abrams SI, Odunsi K and Segal BH. Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice. PLoS ONE. 2013;8(7):e69631.
12. Obermajer N, Muthuswamy R, Odunsi KO, Edwards R and Kalinski P. PGE2-Dependent CXCL12 Production and CXCR4 Expression Control the Accumulation of Human MDSCs in Ovarian Cancer Environment. Cancer Res. 2011.
13. Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez JL, Weaver J, Fiering S and Conejo-Garcia JR. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med. 2012;209(3):495-506.
14. Girvan RC, Knight DA, O'Loughlin CJ, Hayman CM, Hermans IF and Webster GA. MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity. Vaccine. 2011;29(3):545-557.
15. White M, Webster G, O'Sullivan D, Stone S and La Flamme AC. Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis. PLoS ONE. 2014;9(1):e87712.
16. Hamilton MJ, Antignano F, von Rossum A, Boucher JL, Bennewith KL and Krystal G. TLR agonists that induce IFN-beta abrogate resident macrophage suppression of T cells. J Immunol. 2010;185(8):4545-4553.
17. Savina A, Jancic C, Hugues S, Guermonprez P, Vargas P, Moura IC, Lennon-Dumenil AM, Seabra MC, Raposo G and Amigorena S. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell. 2006;126(1):205-218.
18. Jancic C, Savina A, Wasmeier C, Tolmachova T, El-Benna J, Dang PM, Pascolo S, Gougerot-Pocidalo MA, Raposo G, Seabra MC and Amigorena S. Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nat Cell Biol. 2007;9(4):367-378.
19. Tomihara K, Guo M, Shin T, Sun X, Ludwig SM, Brumlik MJ, Zhang B and Curiel TJ. Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells. J Immunol. 2010;184(11):6151-6160.
20. Hume DA. Macrophages as APC and the dendritic cell myth. J Immunol. 2008;181(9):5829-5835.
21. Duan M, Li WC, Vlahos R, Maxwell MJ, Anderson GP and Hibbs ML. Distinct macrophage subpopulations characterize acute infection and chronic inflammatory lung disease. J Immunol. 2012;189(2):946-955.
22. Zaynagetdinov R, Sherrill TP, Kendall PL, Segal BH, Weller KP, Tighe RM and Blackwell TS. Identification of myeloid cell subsets in murine lungs using flow cytometry. Am J Respir Cell Mol Biol. 2013;49(2):180-189.
23. Lumeng CN, Bodzin JL and Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175-184.
24. Maeda T, Noge I and Kagawa Y. Infiltration of M1 macrophages into adipose tissue of ddY-H mice preceding spontaneous appearances of insulin resistance. Biol Pharm Bull. 2013;36(5):825-832.
25. Xu L, Zhu Y, Chen L, An H, Zhang W, Wang G, Lin Z and Xu J. Prognostic value of diametrically polarized tumorassociated macrophages in renal cell carcinoma. Annals of surgical oncology. 2014;21(9):3142-3150.
26. Bozzacco L, Trumpfheller C, Siegal FP, Mehandru S, Markowitz M, Carrington M, Nussenzweig MC, Piperno AG and Steinman RM. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A. 2007;104(4):1289-1294.
27. Tsuji T, Matsuzaki J, Kelly MP, Ramakrishna V, Vitale L, He LZ, Keler T, Odunsi K, Old LJ, Ritter G and Gnjatic S. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J Immunol. 2011;186(2):1218-1227.
28. Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG and de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood. 2012;119(10):2284-2292.
29. Zhang JG, Czabotar PE, Policheni AN, Caminschi I, Wan SS, Kitsoulis S, Tullett KM, Robin AY, Brammananth R, van Delft MF, Lu J, O'Reilly LA, Josefsson EC, Kile BT, Chin WJ, Mintern JD, et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity. 2012;36(4):646-657.
30. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, Garrett-Mayer E, Montero AJ, Bronte V and Mandruzzato S. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 2011;118(8):2254-2265.
31. Gabrilovich DI, Ostrand-Rosenberg S and Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253-268.
32. Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, Kotarski J, Tarkowski R, Wicha M, Cho K, Giordano T, Liu R, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 2013;39(3):611-621.
33. Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N, McFarland-Mancini MM and Drew AF. Macrophages mediate inflammationenhanced metastasis of ovarian tumors in mice. Cancer Res. 2007;67(12):5708-5716.
34. Cieslewicz M, Tang J, Yu JL, Cao H, Zavaljevski M, Motoyama K, Lieber A, Raines EW and Pun SH. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc Natl Acad Sci U S A. 2013;110(40):15919-15924.
35. Gil M, Komorowski MP, Seshadri M, Rokita H, McGray AJ, Opyrchal M, Odunsi KO and Kozbor D. CXCL12/ CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells. J Immunol. 2014;193(10):5327-5337.
36. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A and Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A. 2010;107(18):8363-8368.
37. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23(2):249-262.
38. Bak SP, Walters JJ, Takeya M, Conejo-Garcia JR and Berwin BL. Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res. 2007;67(10):4783-4789.
39. Bak SP, Alonso A, Turk MJ and Berwin B. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol. 2008;46(2):258-268.
40. Balint K, Conejo-Garcia JR, Buckanovich R and Coukos G. Role of vascular leukocytes in ovarian cancer neovascularization. Adv Exp Med Biol. 2008;622:273-280.
41. Peter S, Bak G, Hart K and Berwin B. Ovarian tumorinduced T cell suppression is alleviated by vascular leukocyte depletion. Transl Oncol. 2009;2(4):291-299.
42. Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schworer AM, Wagner U, Muller-Brusselbach S and Muller R. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014;134(1):32-42.
43. Yigit R, Massuger LF, Zusterzeel PL, Pots J, Figdor CG and Torensma R. Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor. Int J Gynecol Cancer. 2011;21(7):1241-1247.
44. Matte I, Lane D, Laplante C, Rancourt C and Piche A. Profiling of cytokines in human epithelial ovarian cancer ascites. American journal of cancer research. 2012;2(5):566-580.
45. Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O'Loughlin KL, Wallace PK, George TC, Peng P, Kelleher RJ, Jr., Odunsi K and Bankert RB. Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-kappaB and NFAT signaling in tumor-associated T cells. Cancer Immun. 2013;13:14.
46. Giuntoli RL, 2nd, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE and Oelke M. Ovarian cancerassociated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009;29(8):2875-2884.
47. Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W and Shrikant PA. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. J Immunol. 2012;188(7):3080-3087.
48. Shrikant P, Khoruts A and Mescher MF. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity. 1999;11(4):483-493.
49. Jackson SH, Gallin JI and Holland SM. The p47phox mouse knock-out model of chronic granulomatous disease. J Exp Med. 1995;182(3):751-758.
50. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG and Terranova PF. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21(4):585-591.